The Aim 100 2023: 10 to 1 investorschronicle.co.uk - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from investorschronicle.co.uk Daily Mail and Mail on Sunday newspapers.
HK-based buyout firm Baring to invest $100m in Chinese drug maker Hutchmed
Source: Michael Longmire/Unsplash
April 9, 2021
Hong Kong-based buyout firm Baring Private Equity Asia has agreed to purchase $100 million worth of shares in Hutchison China MediTech (Hutchmed), a US- and London-listed, commercial-stage, biopharmaceutical firm that aims to treat cancer and immunological diseases.
Baring, one of Asia’s largest private equity (PE) investment houses, plans to acquire nearly 3.28 million American depositary shares (ADS) in Hutchmed at $30.5 apiece through a private placement, according to a statement on Thursday.
Baring is joining Hutchmed’s major shareholders, including US-based investment manager Capital Group, insurer Prudential, and global PE powerhouse General Atlantic, to fund the firm’s ongoing research and clinical development.